Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 3/20 | 0.53 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524769 | 1.00 | MDM2 (0.59) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL29372236 | 1.00 | MDM2 (0.59) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL29370147 | 1.00 | MDM2 (0.59) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL30783486 | 1.00 | MDM2 (0.59) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL30886226 | 1.00 | MDM2 (0.59) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL1738182 | 1.00 | MDM2 (0.59) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL25357595 | 0.99 | MDM2 (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL4600483 | 0.99 | MDM2 (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL21009795 | 0.99 | MDM2 (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL31714126 | 0.99 | MDM2 (0.58) | MDM2KMT2ATLR2TLR1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606348-A | Self-assembled supermolecule nano material responding to AXL kinase and preparation method and application thereof | 东南大学 | 2023-08-18 | — | — | CN | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260069725-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Chengdu StarRay Therapeutics Co., Ltd (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-20060263294-A1 | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-11-23 | — | — | US | disclosed |
| WO-2006114478-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2006-11-02 | — | — | WO | disclosed |
| CN-1720259-A | Tumor targeting agents and uses thereof | KARYON OY (FI) | 2006-01-11 | — | — | CN | disclosed |
| EP-1549667-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549668-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | Karyon OY (FI) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031220-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031218-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031219-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | MDM2 1169/4885KMT2A 3715/4885TLR2 4438/4885 |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | MDM2 4297/4885KMT2A 2244/4885TLR2 1471/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MDM2 3730/4885KMT2A 3406/4885TLR2 2757/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | MDM2 384/4885KMT2A 719/4885TLR2 4179/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | MDM2 4786/4885KMT2A 2065/4885TLR2 442/4885 |
| US-20260069725-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, FOLH1 | MDM2 1518/4885KMT2A 645/4885TLR2 2619/4885 |
| US-20060263294-A1 | Tumor targeting agents and uses thereof | CRACR2A, FGB, EWSR1 | MDM2 1576/4885KMT2A 4667/4885TLR2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.